These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 34368918)

  • 41. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
    Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.
    Chen R; Gultyaev D; Lister J; Han R; Hu N; Malacan J; Solms A; Vashi P; O'Hara J; Hu S
    BMC Med Res Methodol; 2022 Aug; 22(1):215. PubMed ID: 35931967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.
    Oldenburg J; Hay CRM; Jiménez-Yuste V; Peyvandi F; Schved JF; Szamosi J; Winding B; Lethagen S
    BMJ Open; 2019 May; 9(5):e028012. PubMed ID: 31152037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
    Blanchette VS; Shapiro AD; Liesner RJ; Hernández Navarro F; Warrier I; Schroth PC; Spotts G; Ewenstein BM;
    J Thromb Haemost; 2008 Aug; 6(8):1319-26. PubMed ID: 18503631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of one-stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII-Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single-centre, real-world experience of surgery.
    Désage S; Nougier C; Meunier S; Chamouard V; Jousselme E; Dargaud Y; Lienhart A
    Haemophilia; 2024 Mar; 30(2):538-544. PubMed ID: 38149726
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada.
    Matino D; Germini F; Chan AKC; Decker K; Iserman E; Chelle P; Edginton AN; Oladoyinbo O; Trinari E; Keepanasseril A; Iorio A
    Haemophilia; 2024 Mar; 30(2):345-354. PubMed ID: 38379181
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
    Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
    Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
    J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
    Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A.
    Zhang L; Zhao Y; Sun J; Wang X; Yu M; Yang R
    Haemophilia; 2011 Mar; 17(2):191-5. PubMed ID: 20860578
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
    Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A.
    Vashi P; Batt K; Klamroth R; Mancuso ME; Majewska R; Tiede A; Mantovani LG
    J Blood Med; 2021; 12():935-943. PubMed ID: 34754257
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A.
    Auerswald G; Thompson AA; Recht M; Brown D; Liesner R; Guzmán-Becerra N; Dyck-Jones J; Ewenstein B; Abbuehl B
    Thromb Haemost; 2012 Jun; 107(6):1072-82. PubMed ID: 22476554
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.
    Reding MT; Lalezari S; Kenet G; Di Minno G; Ducore J; Solms A; Shah A; Holme PA; Poulsen LH; Meijer K; Simpson M; Mancuso ME
    Drugs R D; 2024 Sep; 24(3):359-381. PubMed ID: 39162954
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa.
    Pitance V; Désage S; Lienhart A; Meunier S; Chamouard V
    Haemophilia; 2021 May; 27(3):e368-e375. PubMed ID: 33780111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
    Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
    Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.
    Oldenburg J; Chambost H; Liu H; Hawes C; You X; Yang X; Newman V; Robinson TM; Hatswell AJ; Hinds D; Santos S; Ozelo M
    Adv Ther; 2024 Jun; 41(6):2267-2281. PubMed ID: 38616241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Switching toward the use of recombinant factor VIII Fc fusion protein Study among 30 patients with severe hemophilia A].
    Sattler L; Raissi A; Fornoff D; Gérout AC; Feugeas O; Grunebaum L; Desprez D
    Ann Biol Clin (Paris); 2020 Feb; 78(1):35-46. PubMed ID: 32108578
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The story of a unique molecule in hemophilia A: recombinant single-chain factor VIII.
    Pabinger-Fasching I
    Thromb Res; 2016 May; 141 Suppl 3():S2-4. PubMed ID: 27288063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.